PriceTargets.com logo

NASDAQ:ALKS - Alkermes Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $30.67
  • Forecasted Upside: 3.36 %
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$29.67 As of 05/17/2022 04:59 PM ET
▲ +0.74 (2.56%)

This chart shows the closing price for ALKS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alkermes Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALKS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALKS

Analyst Price Target is $30.67
▲ +3.36% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $30.67, with a high forecast of $36.00 and a low forecast of $25.00. The average price target represents a 3.36% upside from the last price of $29.67.

This chart shows the closing price for ALKS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 contributing investment analysts is to hold stock in Alkermes. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
11/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
2/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
8/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
11/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
2/16/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
4/17/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
5/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/28/2022MizuhoBoost Price Target$35.00 ➝ $36.00High
4/28/2022HC WainwrightBoost Price Target$30.00 ➝ $32.00High
4/27/2022Stifel NicolausBoost Price Target$24.00 ➝ $27.00High
4/21/2022SVB LeerinkBoost Price TargetMarket Perform$24.00 ➝ $25.00Low
4/20/2022The Goldman Sachs GroupInitiated CoverageBuy$35.00Medium
3/22/2022CitigroupBoost Price TargetNeutral$22.00 ➝ $26.00High
2/17/2022MizuhoBoost Price Target$33.00 ➝ $35.00High
1/27/2022Cantor FitzgeraldUpgradeHold ➝ Overweight$32.00High
12/1/2021CitigroupInitiated CoverageNeutral$22.00High
11/9/2021MizuhoLower Price TargetNeutral$36.00 ➝ $33.00High
11/9/2021SVB LeerinkLower Price TargetMarket Perform$27.00 ➝ $24.00High
10/28/2021HC WainwrightBoost Price TargetNeutral$25.00 ➝ $30.00Medium
10/27/2021Stifel NicolausBoost Price TargetHold$25.00 ➝ $29.00Medium
10/6/2021Jefferies Financial GroupUpgradeHold ➝ Buy$36.00High
9/10/2021MizuhoReiterated RatingBuy$33.00 ➝ $36.00Medium
9/2/2021Bank of AmericaDowngradeNeutral ➝ Underperform$25.00 ➝ $27.00Low
7/29/2021SVB LeerinkBoost Price TargetMarket Perform$23.00 ➝ $25.00Low
7/29/2021MizuhoBoost Price TargetBuy$29.00 ➝ $33.00Low
6/2/2021HC WainwrightBoost Price TargetNeutral$24.00 ➝ $25.00Low
6/1/2021MizuhoReiterated RatingBuy$29.00High
4/29/2021HC WainwrightBoost Price TargetNeutral$23.00 ➝ $24.00Low
4/26/2021MizuhoBoost Price TargetBuy$28.00 ➝ $29.00High
1/7/2021MizuhoBoost Price Target$24.00 ➝ $28.00N/A
12/11/2020SVB LeerinkBoost Price TargetMarket Perform$18.00 ➝ $23.00Medium
11/10/2020HC WainwrightReiterated RatingHoldLow
10/15/2020MizuhoUpgradeNeutral ➝ Buy$19.00 ➝ $24.00Low
10/7/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
9/30/2020Bank of AmericaLower Price TargetNeutral$21.00 ➝ $19.00Medium
9/21/2020JPMorgan Chase & Co.Reiterated RatingHoldLow
7/30/2020HC WainwrightReiterated RatingHold$23.00Medium
7/30/2020MizuhoBoost Price TargetNeutral$16.00 ➝ $19.00High
7/30/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$19.00 ➝ $15.00High
4/30/2020HC WainwrightReiterated RatingNeutral$25.00 ➝ $23.00High
4/29/2020Piper SandlerLower Price TargetNeutral$22.00 ➝ $21.00High
4/29/2020Stifel NicolausLower Price TargetAverage ➝ Hold$20.00 ➝ $17.00High
4/29/2020MizuhoReiterated RatingHold$16.00High
4/2/2020Morgan StanleyLower Price TargetEqual Weight$20.00 ➝ $16.00Low
3/23/2020Bank of AmericaLower Price TargetNeutral$20.00 ➝ $17.00Medium
2/14/2020HC WainwrightLower Price TargetNeutral$26.00 ➝ $25.00High
2/14/2020Bank of AmericaDowngradeBuy ➝ Neutral$31.00 ➝ $20.00High
2/14/2020CowenReiterated RatingBuy$28.00High
2/13/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$25.00 ➝ $21.00Low
2/13/2020Stifel NicolausLower Price TargetHold$23.00 ➝ $20.00Low
2/5/2020MizuhoInitiated CoverageNeutral$19.00Medium
1/31/2020Wolfe ResearchUpgradeUnderperform ➝ Peer Perform$21.00Low
1/24/2020SVB LeerinkReiterated RatingMarket PerformLow
1/24/2020CowenReiterated RatingBuyHigh
11/1/2019HC WainwrightLower Price TargetNeutral$28.00 ➝ $26.00Low
10/23/2019Stifel NicolausLower Price TargetHold$25.00 ➝ $23.00High
10/18/2019HC WainwrightReiterated RatingHold$28.00Low
9/13/2019CowenSet Price TargetBuy$34.00High
9/5/2019Morgan StanleyUpgradeUnderweight ➝ Equal$30.00 ➝ $20.00Medium
7/26/2019CitigroupSet Price TargetHold$25.00N/A
7/25/2019Piper Jaffray CompaniesLower Price TargetNeutral$30.00 ➝ $22.00Medium
7/15/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral$27.00High
5/31/2019HC WainwrightInitiated CoverageNeutral ➝ Neutral$28.00 ➝ $28.00High
5/1/2019CitigroupDowngradeBuy ➝ Neutral$62.00 ➝ $33.00High
4/26/2019Credit Suisse GroupSet Price TargetSell$28.00Medium
4/10/2019JPMorgan Chase & Co.Reiterated RatingBuyHigh
2/15/2019Credit Suisse GroupUpgradeHold$30.00High
2/15/2019Stifel NicolausLower Price TargetHold$40.00 ➝ $34.00N/A
1/23/2019Cantor FitzgeraldSet Price TargetHold$33.00Low
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
12/18/2018The Goldman Sachs GroupDowngradeNeutral ➝ Sell$49.00 ➝ $26.00High
12/14/2018Wolfe ResearchInitiated CoverageUnderperform ➝ UnderperformMedium
12/13/2018Credit Suisse GroupDowngradeOutperform ➝ Underperform$47.00 ➝ $31.00High
11/12/2018SVB LeerinkInitiated CoverageMarket Perform$36.00Medium
11/5/2018Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$46.00 ➝ $41.00High
11/5/2018Piper Jaffray CompaniesInitiated CoverageNeutral ➝ Neutral$40.00Low
11/2/2018Stifel NicolausLower Price TargetHold$44.00 ➝ $40.00High
10/30/2018CowenReiterated RatingBuy$58.00Medium
10/23/2018Cantor FitzgeraldReiterated RatingHold$46.00Low
8/6/2018Stifel NicolausInitiated CoverageHold$45.00Low
7/27/2018Credit Suisse GroupLower Price TargetOutperform ➝ Buy$57.00 ➝ $51.00High
7/27/2018Bank of AmericaLower Price TargetBuy ➝ Buy$56.00 ➝ $54.00High
7/8/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
7/2/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
6/28/2018Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
6/21/2018Morgan StanleyDowngradeEqual Weight ➝ Underweight$67.00 ➝ $42.00High
6/6/2018B. RileyInitiated CoverageBuy$60.00High
5/31/2018CitigroupUpgradeNeutral ➝ BuyMedium
5/16/2018CitigroupUpgradeNeutral ➝ Buy$62.00High
5/11/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$56.00Medium
4/27/2018Credit Suisse GroupSet Price TargetBuy$57.00Low
4/16/2018Credit Suisse GroupSet Price TargetBuy$63.00Medium
4/3/2018JPMorgan Chase & Co.Set Price TargetBuy$63.00High
4/2/2018CowenLower Price TargetOutperform$55.00High
4/2/2018Credit Suisse GroupReiterated RatingBuy$53.00High
4/2/2018Cantor FitzgeraldLower Price TargetNeutral$45.00High
2/23/2018Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$60.00 ➝ $67.00Medium
2/22/2018Jefferies Financial GroupDowngradeBuy ➝ Hold$63.19 ➝ $66.00High
2/20/2018Cantor FitzgeraldReiterated RatingHold$50.00Medium
2/16/2018Credit Suisse GroupBoost Price TargetOutperform$66.00 ➝ $70.00High
2/15/2018CitigroupSet Price TargetHold$62.00High
2/14/2018Credit Suisse GroupSet Price TargetBuy$66.00High
11/28/2017Credit Suisse GroupSet Price TargetBuy$66.00Medium
10/27/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00N/A
10/27/2017UBS GroupSet Price TargetHold$57.00 ➝ $54.00N/A
10/27/2017Credit Suisse GroupLower Price TargetOutperform$70.00 ➝ $66.00N/A
10/26/2017BarclaysSet Price TargetHold$50.00N/A
10/26/2017CitigroupSet Price TargetHold$62.00N/A
10/21/2017MizuhoSet Price TargetBuy$81.00N/A
10/16/2017BarclaysDowngradeOverweight ➝ Equal Weight$66.00 ➝ $50.00N/A
8/25/2017Jefferies Financial GroupSet Price TargetBuy$69.00Low
7/1/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00Low
6/13/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$68.00 ➝ $61.00Medium
6/7/2017Credit Suisse GroupReiterated RatingBuy$70.00Low
5/19/2017Credit Suisse GroupSet Price TargetBuy$70.00Low
(Data available from 5/17/2017 forward)

News Sentiment Rating

0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2021
  • 5 very positive mentions
  • 22 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
11/18/2021
  • 0 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2021
  • 1 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
1/17/2022
  • 2 very positive mentions
  • 22 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2022
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/18/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/17/2022
  • 5 very positive mentions
  • 38 positive mentions
  • 17 negative mentions
  • 2 very negative mentions
Mentions as of
5/17/2022

Current Sentiment

  • 5 very positive mentions
  • 38 positive mentions
  • 17 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Alkermes logo
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $29.67
Low: $28.81
High: $29.85

50 Day Range

MA: $27.58
Low: $23.57
High: $30.38

52 Week Range

Now: $29.67
Low: $21.24
High: $33.00

Volume

62,758 shs

Average Volume

1,996,310 shs

Market Capitalization

$4.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Alkermes?

The following sell-side analysts have issued stock ratings on Alkermes in the last year: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Jefferies Financial Group Inc., Mizuho, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ALKS.

What is the current price target for Alkermes?

9 Wall Street analysts have set twelve-month price targets for Alkermes in the last year. Their average twelve-month price target is $30.67, suggesting a possible upside of 6.0%. Jefferies Financial Group Inc. has the highest price target set, predicting ALKS will reach $36.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $25.00 for Alkermes in the next year.
View the latest price targets for ALKS.

What is the current consensus analyst rating for Alkermes?

Alkermes currently has 1 sell rating, 5 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALKS, but not buy more shares or sell existing shares.
View the latest ratings for ALKS.

How do I contact Alkermes' investor relations team?

Alkermes' physical mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company's listed phone number is (531) 772-8000 and its investor relations email address is [email protected] The official website for Alkermes is www.alkermes.com. Learn More about contacing Alkermes investor relations.